Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL872346 | 1.00 | CYP17A1 (0.33) | CYP17A1CHRNA4EPHX2 | |
| SCHEMBL110926 | 0.78 | — | — | |
| SCHEMBL17675557 | 0.74 | EIF2AK4 (0.34) | — | |
| SCHEMBL8060559 | 0.72 | L3MBTL1 (0.36) | — | |
| Formic Acid SCHEMBL28961942 | 0.72 | CHRNA4 (0.31) | CHRNA4 | |
| SCHEMBL871800 | 0.71 | NPC1 (0.41) | — | |
| SCHEMBL16992452 | 0.69 | SLC18A3 (0.41) | — | |
| SCHEMBL21162011 | 0.69 | KDM1A (0.31) | — | |
| Hydrochloric Acid SCHEMBL21079740 | 0.68 | KDM1A (0.30) | — | |
| Hydrochloric Acid SCHEMBL21079742 | 0.68 | KDM1A (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225556-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| US-8420629-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-8158616-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120077798-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-03-29 | — | — | US | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225556-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | CYP17A1 1755/4885CHRNA4 4245/4885EPHX2 2996/4885 |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | CYP17A1 1755/4885CHRNA4 4245/4885EPHX2 2996/4885 |
| US-20120077798-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | CYP17A1 1755/4885CHRNA4 4245/4885EPHX2 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.